Sanofi Q1 earnings: Altuviiio closing in on blockbuster status, Dupixent...
Sanofi posted a strong set of first-quarter results Thursday morning, with its recombinant factor drug Altuviiio on track to become a blockbuster drug and its crown jewel Dupixent continuing to draw...
View ArticleMerck Q1 earnings: Gardasil sales hit by China market pressure
Sales of Merck’s HPV vaccine plummeted 41% in the first quarter, as the company continues to deal with lower demand in China. Gardasil is Merck’s second-biggest product behind its megablockbuster...
View ArticleRoche takes steps to protect itself from tariffs, while Sanofi hangs back
Roche and Sanofi said on Thursday morning they have been running scenarios on how US and other tariffs could potentially impact their respective businesses. However, while Roche has detailed specific...
View ArticleThermo Fisher buckles up for US-China trade war, budgets $2B to ease impact
Thermo Fisher Scientific has warned it could lose out on nearly $1 billion in revenue this year due to the US-China tariff war and NIH funding cuts. Because of the "substantial" US tariff rates on ...
View ArticleBristol Myers Q1 earnings: Transition continues as drugmaker raises guidance
Bristol Myers Squibb’s evolution after sweeping cost-cutting measures kept chugging along as the company reported first-quarter earnings Thursday morning. While overall revenue declined by 6% to $11.2...
View ArticleVersant's latest biotech focuses on inflammatory diseases
Versant Ventures' biotech incubation team has launched another Swiss startup, this time focused on a pair of antibodies for autoimmune and inflammatory diseases. Granite Bio broke cover on Thursday...
View ArticleAvidicure's $50M seed round; Flagship's new AI company that detects disease
Plus, news about Novo Holdings, Bioxodes and Tempus AI: Dutch biotech raises $50M in seed funding: Avidicure, which is developing avidity engineered antibodies for cancer, said it plans to use the...
View ArticleLotte Bio launches ADC services; Ypsomed to focus on self-injection business
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Lotte Biologics has launched its ADC services and it has signed its ...
View ArticleBristol Myers CEO signals dealmaking will be a top priority in 2025
Is Bristol Myers Squibb ready to take on big dealmaking again? When CEO Chris Boerner took over in late 2023, Bristol Myers was in a difficult position. Its stock price {$BMY} was down more than ...
View ArticleThe potential of all-AI labs
Picture this: A chemist, biologist and computer scientist are working together in a lab. But in this case, they’re all AI agents trained on reams of papers and data, working in a virtual lab run ...
View ArticleHalozyme launches patent fight over Merck's injectable Keytruda
San Diego biotech Halozyme is suing Merck over an injectable version of its blockbuster cancer drug, alleging that the new formulation will infringe on Halozyme's under-the-skin delivery patents. The...
View ArticleCassidy urges major reforms to 340B drug discount program
The growing drug discount program for low-income Americans, known as the 340B program, has "transparency and oversight concerns" and needs to be reformed, Sen. Bill Cassidy (R-LA), chair of the Senate...
View ArticleDrugmakers prepare for manageable tariff hit to business, earnings
For the drug industry, President Donald Trump's tariffs haven't started to really hurt. At least not yet. On Thursday, several of the world’s largest pharma companies — Merck, Bristol Myers Squibb,...
View ArticleBiosimilar launch challenges remain, report finds
As President Donald Trump has sought to speed the development and approval of new biosimilar competition to expensive biologics, only 66% of FDA-approved biosimilars have actually been commercialized,...
View ArticleMerck is well-stocked on Keytruda as pharma tariffs loom, CEO says
Merck CEO Rob Davis told investors on Thursday that he’s confident in the company’s ability to protect its top-selling product from the potential impacts of industry-specific tariffs. Without going...
View ArticleCaribou lays off 32% of staff, cuts lupus program
Caribou Biosciences is paring down its pipeline and cutting about a third of its workforce as cell and gene therapy companies continue to struggle amid a bleak biotech market. Caribou said Thursday...
View ArticleGilead Q1 earnings: Strong HIV business balances out low Covid and cancer...
Gilead’s HIV drug business grew while its Covid drug sales tanked in the first quarter of 2025, as the company recorded the same amount of revenue compared to this time last year. The Foster City ...
View ArticleMerck KGaA closes in on SpringWorks deal at $3.5B price point
Merck KGaA said Thursday that its late-stage discussions to buy the rare cancer biotech SpringWorks Therapeutics have landed on a likely price of $47 per share. That would put the value of the pending...
View ArticlePaul Stoffels on retiring from Galapagos; Boehringer Ingelheim switches up...
When the board of Belgian biotech Galapagos asked Paul Stoffels to become CEO, he told them he was only interested in doing the job for two to three years. Galapagos — a company he helped found ...
View ArticleAbbVie Q1 earnings: Immunology still a powerhouse as Skyrizi, Rinvoq hit $5B...
One quarter after AbbVie raised future sales estimates due to the successes of its immunology portfolio, the company again saw higher-than-expected revenues to start 2025. AbbVie’s overall revenues for...
View Article